PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer
Post author correction
Article Type: ORIGINAL RESEARCH ARTICLE
Article Subject: Prognostic/Predictive Biomarkers & Target Therapy
AuthorsWensong Wei, Yufeng Zou, Qihua Jiang, Zhibin Zhou, Haolong Ding, Liping Yan, Shixin Yang
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, characterized by advanced disease stage and poor prognosis. Moreover, due to the lack of therapeutic markers, TNBC patients can't benefit fully from currently available targeted therapies.
To fully understand the molecular basis of TNBC, we used gene set enrichment analysis (GSEA) to screen out the most altered functional module in TNBC, from publicly available microarray data and studied the association of the candidate gene with TNBC development.
We found that the proteasome was significantly activated in TNBC. As compared with other breast cancer subtypes and normal tissue, proteasome subunit beta 5 (PSMB5), the key regulator of proteasome function, was overexpressed in TNBC tissue and predictive of poor prognosis. Moreover, we also found that PSMB5 knockdown induced TNBC apoptosis and significantly enhanced cancer cell sensitivity to the chemotherapeutic agents bortezomib and paclitaxel.
Our results suggest a potential role for PSMB5 as a biomarker and therapeutic target for TNBC.
- • Accepted on 18/05/2017
- • Available online on 15/06/2017
This article is available as full text PDF.
- Wei, Wensong [PubMed] [Google Scholar]
- Zou, Yufeng [PubMed] [Google Scholar]
- Jiang, Qihua [PubMed] [Google Scholar]
- Zhou, Zhibin [PubMed] [Google Scholar]
- Ding, Haolong [PubMed] [Google Scholar]
- Yan, Liping [PubMed] [Google Scholar]
- Yang, Shixin [PubMed] [Google Scholar] , * Corresponding Author (ShixinYang01@gmail.com)
Department of Breast Cancer, The Third Hospital of Nanchang City, Nanchang, Jiangxi - PR China